Ifinatamab Deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC). According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Ifinatamab Deruxtecan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ifinatamab Deruxtecan is expected to reach an annual total of $47 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ifinatamab Deruxtecan Overview
Ifinatamab deruxtecan (DS-7300) is under development for the treatment of solid tumors including advanced or metastatic head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, squamous and adenocarcinoma of non-small cell lung cancer (NSCLC), small-cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer and breast cancer.
It is also under development for pretreated extensive-stage small cell lung cancer (ES-SCLC). It targets B7-H3/CD276 antigen. The drug candidate is based on antibody drug conjugate (ADC) technology. It is administered through intravenous route as a solution. The drug candidate comprises of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker.
Daiichi Sankyo Overview
Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY1,044,892 million for the fiscal year ended March 2022 (FY2022), an increase of 8.6% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 7% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 7.9% in FY2021. The company reported revenues of JPY340,479 million for the third quarter ended December 2022, an increase of 4% over the previous quarter.
For a complete picture of Ifinatamab Deruxtecan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.